L'Oréal Shares Fall 1.23% at Close in Limited Trading Volume
L'Oréal shares experienced a decline at the close on Monday, December 22, dropping 1.23% to 366.45 euros from 371 euros the previous day. The trading volumes remained modest with only 0.04% of the capital traded during the session, indicating investors' caution during the year-end period. Despite a slightly negative weekly trend of 0.97% and a quarterly consolidation of 0.87%, the French cosmetics giant maintains a positive annual performance of 8.76%, demonstrating relative resilience in a contrasting market environment marked by geopolitical and economic uncertainties. The stock price is now below its 50-day moving average of 368.78 euros, signaling a stabilization phase after recent movements.
Recent Developments and Strategic Acquisitions
The recent news from the group has been dominated by the announcement on December 8 of the acquisition of an additional 10% in Galderma Group AG from a consortium led by EQT, increasing L'Oréal's total stake to 20% for an undisclosed amount. This move is part of the group's strategy to position itself in the rapidly growing market of medical aesthetics and dermatology. A few days later, on December 12, L'Oréal received for the tenth consecutive year the triple AAA rating from the CDP organization, becoming the first and only company in the world to achieve this decennial distinction for its performance in climate, forests, and water security. These announcements follow the historic acquisition of Kering Beauté for 4 billion euros announced in October, a transaction that is the largest in the group's history and aims to consolidate its position as a global leader in the luxury perfume sector.
Technical Analysis and Market Position
From a technical analysis perspective, the stock shows an RSI of 41, indicating a relative balance between buyers and sellers without a marked overselling signal, leaving room for investor maneuver. The MACD configuration remains slightly constructive with a MACD line at 2.88 points almost aligned with the signal line at 2.87 points, generating a minimal positive histogram of 0.01 point suggesting a very subdued short-term bullish dynamic. The stock price is positioned between a support threshold identified at 350.65 euros and a resistance at 377.95 euros, offering a variation range of about 7.5% in both directions. The moderate monthly volatility of 4.34% and a very low beta of 0.24 confirm a relatively decoupled evolution from the movements of the CAC 40. Investors will await the 2025 annual results scheduled for February 12, 2026, to assess the group's prospects after a year marked by an ambitious acquisition strategy and repositioning towards high-growth segments of dermatology and medical aesthetics.
